EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Divergent CMV and EBV co-infection impact in adult and pediatric hematopoietic stem cell transplantation recipients

Osama Alsmadi, Hasan Hashem, Khalid Halahleh, Jude Jarrah, Yazan Talab, Iyad Sultan, Maysa Al-Hussaini

Frontiers in Cellular and Infection Microbiology · 2026

DOI: 10.3389/fcimb.2026.1793798 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Osama Alsmadi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Therapy and Applied Genomics, King Hussein Cancer Center, Amman, Jordan. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Infections, Cytomegalovirus Infections, Coinfection. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivations are major complications after hematopoietic stem cell transplantation (HCT), but co-infection epidemiology and outcomes in combined adult-pediatric cohorts remain poorly defined. Materials and methods This retrospective single-center study analyzed 941 consecutive HCT recipients (2015–2023). CMV and EBV were quantified by whole-blood qPCR (positivity ≥153 and ≥433 copies/mL, respectively). CMV testing was weekly until day +100 post-HSCT; EBV testing followed clinical indication at the treating physician’s discretion. IgG serostatus is not routinely tested at KHCC for post-transplant monitoring. Acknowledging some missing values, we evaluated the incidence, risk factors, and survival impact of CMV/EBV co-infection using chi-square tests, Kaplan-Meier analysis, and multivariable logistic and Cox proportional-hazards regression.

Results

Among 941 recipients (56.5% adult, 43.5% pediatric), adults received 89.1% of CMV tests (838/941) and 76.6% of CMV infections (105/137), whereas pediatric patients accounted for 59.8% of EBV infections (76/127); EBV testing covered 65.5% (616/941). Co-infection incidence was 7.6% (70/916). Co-infection was significantly associated with allogeneic transplant (p=0.004), haploidentical donor (p=0.010), reduced-intensity conditioning (p=0.017), and acute graft-versus-host disease (aGVHD) (p=0.028), but not with malignancy status (54/70 [77.1%] vs. 577/760 [75.9%] malignant; p=0.819); haploidentical (vs. related) donor type remained independent on multivariable analysis (adjusted OR 2.01, 95% CI 1.18–3.41, p=0.0098). CMV monoinfection was associated with adult age and haploidentical transplantation; EBV monoinfection with pediatric age, non-malignant disease, and aGVHD. Pediatric 3-year overall survival (OS) was superior (78.4% vs. 64.6%; median follow-up 41.8 months). The difference in 3-year OS between co-infected (67.3%) and non-co-infected (70.9%) patients did not reach statistical significance (Kaplan–Meier log-rank p = 0.4046; crude mortality by Pearson chi-square, p = 0.286); chronic GVHD was the only independent predictor of OS (adjusted HR 0.016, 95% CI 0.002–0.150, p=0.0003).

Conclusion

CMV and EBV post-HCT exhibit distinct, age-associated risk profiles, and co-infection defines a high-risk phenotype linked to intensive immunosuppression and aGVHD. Three-year OS did not differ significantly between groups; given the observational design, selection bias from non-uniform EBV testing, and possible type II error, this should not be taken as evidence that pre-emptive strategies eliminate the survival impact of co-infection. Findings support age- and risk-adapted viral monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationEpstein-Barr Virus InfectionsCytomegalovirus InfectionsCoinfectionTransplant RecipientsHumansFemaleRetrospective StudiesAdultMaleChildAdolescentChild, PreschoolMiddle AgedHerpesvirus 4, HumanRisk FactorsCytomegalovirusIncidenceYoung AdultInfantGraft vs Host DiseaseAged

Stichwörter der Autor:innen

EBV_CMVGvHD (graft-versus-host disease)adultco-infectionpediatricsstem cell transplant (SCT)

Autor:innen und Institutionen

  • Department of Cell Therapy and Applied Genomics, King Hussein Cancer Center, Amman, Jordan.
  • Faculty of Allied Medical Sciences, Applied Science University, Amman, Jordan.
  • Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
  • Artificial Intelligence and Data Innovation Office, King Hussein Cancer Center, Amman, Jordan.

Zitieren

APA

Alsmadi, O., Hashem, H., Halahleh, K., Jarrah, J., Talab, Y., Sultan, I., & Al-Hussaini, M. (2026). Divergent CMV and EBV co-infection impact in adult and pediatric hematopoietic stem cell transplantation recipients. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1793798

Vancouver

Alsmadi O, Hashem H, Halahleh K, Jarrah J, Talab Y, Sultan I, et al. Divergent CMV and EBV co-infection impact in adult and pediatric hematopoietic stem cell transplantation recipients. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1793798

BibTeX
@article{Alsmadi2026,
  author = {Alsmadi, Osama and Hashem, Hasan and Halahleh, Khalid and Jarrah, Jude and Talab, Yazan and Sultan, Iyad and Al-Hussaini, Maysa},
  title = {Divergent CMV and EBV co-infection impact in adult and pediatric hematopoietic stem cell transplantation recipients},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  doi = {10.3389/fcimb.2026.1793798}
}
Kostenlos starten →